Unknown

Dataset Information

0

Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.


ABSTRACT: INTRODUCTION: Since treatment modalities for metastatic recurrent triple-negative breast cancer (mrTNBC) are limited, a novel treatment approach including immunotherapy is required. We have developed a novel regimen of personalized peptide vaccination (PPV), in which vaccine antigens are individually selected from a pool of different peptide candidates based on the pre-existing host immunity. Herein we conducted a phase II study of PPV for metastatic recurrent breast cancer patients to investigate the feasibility of PPV for mrTNBC. METHODS: Seventy-nine patients with metastatic recurrent breast cancer who had metastases and had failed standard chemotherapy and/or hormonal therapy were enrolled. They were subgrouped as the mrTNBC group (n = 18), the luminal/human epidermal growth factor receptor 2 (HER2)-negative group (n = 41) and the HER2-positive group (n = 18), while the remaining two patients had not been investigated. A maximum of four human leukocyte antigen (HLA)-matched peptides showing higher peptide-specific immunoglobulin G (IgG) responses in pre-vaccination plasma were selected from 31 pooled peptide candidates applicable for the four HLA-IA phenotypes (HLA-A2, -A24, or -A26 types, or HLA-A3 supertypes), and were subcutaneously administered weekly for 6 weeks and bi-weekly thereafter. Measurement of peptide-specific cytotoxic T lymphocyte (CTL) and IgG responses along with other laboratory analyses were conducted before and after vaccination. RESULTS: No severe adverse events associated with PPV were observed in any of the enrolled patients. Boosting of CTL and/or IgG responses was observed in most of the patients after vaccination, irrespective of the breast cancer subtypes. There were three complete response cases (1 mrTNBC and 2 luminal/HER2-negative types) and six partial response cases (1 mrTNBC and 5 luminal/HER2-negative types). The median progression-free survival time and median overall survival time of mrTNBC patients were 7.5 and 11.1 months, while those of luminal/HER2-negative patients were 12.2 and 26.5 months, and those of HER2-positive patients were 4.5 and 14.9 months, respectively. CONCLUSIONS: PPV could be feasible for mrTNBC patients because of the safety, immune responses, and possible clinical benefits. CLINICAL TRIAL REGISTRATION NUMBER: UMIN000001844 (Registration Date: April 5, 2009).

SUBMITTER: Takahashi R 

PROVIDER: S-EPMC4227005 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.

Takahashi Ryuji R   Toh Uhi U   Iwakuma Nobutaka N   Takenaka Miki M   Otsuka Hiroko H   Furukawa Mina M   Fujii Teruhiko T   Seki Naoko N   Kawahara Akihiko A   Kage Masayoshi M   Matsueda Satoko S   Akagi Yoshito Y   Yamada Akira A   Itoh Kyogo K   Sasada Tetsuro T  

Breast cancer research : BCR 20140703 4


<h4>Introduction</h4>Since treatment modalities for metastatic recurrent triple-negative breast cancer (mrTNBC) are limited, a novel treatment approach including immunotherapy is required. We have developed a novel regimen of personalized peptide vaccination (PPV), in which vaccine antigens are individually selected from a pool of different peptide candidates based on the pre-existing host immunity. Herein we conducted a phase II study of PPV for metastatic recurrent breast cancer patients to in  ...[more]

Similar Datasets

| S-EPMC10833221 | biostudies-literature
| S-EPMC3979114 | biostudies-literature
| S-EPMC5581512 | biostudies-literature
| S-EPMC6916124 | biostudies-literature
| S-EPMC8184866 | biostudies-literature
| S-EPMC8092567 | biostudies-literature
| S-EPMC7989121 | biostudies-literature
| S-EPMC8150754 | biostudies-literature
| S-EPMC5715265 | biostudies-literature
| S-EPMC5313267 | biostudies-literature